Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Surface Oncology, Inc. (NASDAQ: SURF).

Full DD Report for SURF

You must become a subscriber to view this report.


Recent News from (NASDAQ: SURF)

Surface Oncology Announces Upcoming Investor Presentations
CAMBRIDGE, Mass., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced this morning that it will host presentations at two investor confere...
Source: GlobeNewswire
Date: November, 20 2018 07:00
Stocks To Watch: Was That A Speed Bump?
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. That escalated quickly. While we gave a gentle reminder last week that interest rat...
Source: SeekingAlpha
Date: October, 13 2018 09:45
Trillium Therapeutics Updates On Lead Lymphoma Trials
Trillium Therapeutics ( TRIL ) is a Canadian biopharmaceutical company developing fusion-proteins targeting CD47, an immune checkpoint inhibitor involved in suppression of the innate immune system (macrophages). If you are new to the CD47 story, I recommend you start here . Last week, Trill...
Source: SeekingAlpha
Date: October, 04 2018 18:51
Surface Oncology to Present at the Baird 2018 Global Healthcare Conference
CAMBRIDGE, Mass., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, and Vito Palombella, Ph...
Source: GlobeNewswire
Date: August, 30 2018 09:59
Surface Oncology reports Q2 results
Surface Oncology (NASDAQ: SURF ): Q2 EPS of -$0.73 More news on: Surface Oncology, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 14 2018 07:07
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2018
CAMBRIDGE, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Surface Oncology  (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second q...
Source: GlobeNewswire
Date: August, 14 2018 07:00
47 Scoop: Trillium Bleeds, Surface Hemorrhages, And Forty Seven Throws In The $47 Million Towel On Synthon Lawsuit
CD47, a novel immune checkpoint in the innate immune system, is a rapidly emerging target in cancer immunotherapy. Previously, I spoke to the merits of the technology and the key drivers fueling a cohort of 8 companies developing CD47-directed therapies. Today, I provide updated commentary o...
Source: SeekingAlpha
Date: August, 01 2018 16:46
Your Daily Pharma Scoop: Redhill Zooms, FDA Nods Advaxis Ahead, Hologic Warned
Stocks in News: RDHL, ADXS RedHill's RHB-104 successful in late-stage Crohn's study; shares up 40% premarket Discussion : RedHill Biopharma’s ( RDHL ) RB-104 succeeds in Phase 3 clinical trial on Crohn's disease patients. Primary endpoint of remission at 26th week against the d...
Source: SeekingAlpha
Date: July, 31 2018 08:29
FDA Grants Orphan Drug Designation to Surface Oncology's SRF231 for the Treatment of Multiple Myeloma
CAMBRIDGE, Mass., July 30, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug Administration (FDA) has granted orp...
Source: GlobeNewswire
Date: July, 30 2018 14:24
Company Profile: Surface Oncology
Surface Oncology (SURF) is a clinical-stage biopharmaceutical company with clinical assets targeting CD47 and CD73. If you are a new investor to the CD47 story, I recommend you start here . Clinical Pipeline SURF has two compounds in ongoing phase 1 trials, SRF-231 and SRF-373, with two m...
Source: SeekingAlpha
Date: July, 22 2018 13:44

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-089.7710.2510.339.6090,012
2018-05-1713.7513.9914.11513.75129,627

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1314,75142,17734.9740Cover
2018-12-1217,93454,91532.6577Cover
2018-12-117,86823,42333.5909Cover
2018-12-106,53029,68721.9962Cover
2018-12-0710,72529,31936.5804Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SURF.


About Surface Oncology, Inc. (NASDAQ: SURF)

Logo for Surface Oncology, Inc. (NASDAQ: SURF)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: SURF)

      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: April, 25 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: April, 23 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 23 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: April, 23 2018
      Prospectus filed under Rule 424(b)(4)
      Filing Type: 424B4Filing Source: edgar
      Filing Date: April, 20 2018
      Filing Type: CERTFiling Source: edgar
      Filing Date: April, 18 2018
      Registration of up to an additional 20% of securities for any offering registered on an S-1
      Filing Type: S-1MEFFiling Source: edgar
      Filing Date: April, 18 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 18 2018
      Notice from the SEC of registration effectiveness
      Filing Type: EFFECTFiling Source: edgar
      Filing Date: April, 18 2018
      Registration of certain classes of securities 12(b) of the Securities Exchange Act
      Filing Type: 8-A12BFiling Source: edgar
      Filing Date: April, 17 2018

       

       


      Daily Technical Chart for (NASDAQ: SURF)

      Daily Technical Chart for (NASDAQ: SURF)


      Stay tuned for daily updates and more on (NASDAQ: SURF)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: SURF)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SURF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of SURF and does not buy, sell, or trade any shares of SURF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/